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Abstract
Background: Although pregabalin therapy is beneficial for neuropathic pain (NeP) by targeting the CaVa2δ-1
subunit, its site of action is uncertain. Direct targeting of the central nervous system may be beneficial for the
avoidance of systemic side effects.
Results: We used intranasal, intrathecal, and near-nerve chamber forms of delivery of varying concentrations of
pregabalin or saline delivered over 14 days in rat models of experimental diabetic peripheral neuropathy and
spinal nerve ligation. As well, radiolabelled pregabalin was administered to determine localization with different
deliveries. We evaluated tactile allodynia and thermal hyperalgesia at multiple time points, and then analyzed
harvested nervous system tissues for molecular and immunohistochemical changes in CaVa2δ-1 protein expression.
Both intrathecal and intranasal pregabalin administration at high concentrations relieved NeP behaviors, while near-
nerve pregabalin delivery had no effect. NeP was associated with upregulation of CACNA2D1 mRNA and CaVa2δ-1
protein within peripheral nerve, dorsal root ganglia (DRG), and dorsal spinal cord, but not brain. Pregabalin’s effect
was limited to suppression of CaVa2δ-1 protein (but not CACNA2D1 mRNA) expression at the spinal dorsal horn in
neuropathic pain states. Dorsal root ligation prevented CaVa2δ-1 protein trafficking anterograde from the dorsal
root ganglia to the dorsal horn after neuropathic pain initiation.
Conclusions: Either intranasal or intrathecal pregabalin relieves neuropathic pain behaviours, perhaps due to
pregabalin’s effect upon anterograde CaVa2δ-1 protein trafficking from the DRG to the dorsal horn. Intranasal
delivery of agents such as pregabalin may be an attractive alternative to systemic therapy for management of
neuropathic pain states.
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Background
Neuropathic pain is a consequence of nerve damage or
disease in the central and/or peripheral nervous system
such as with diabetes and trauma. The clinical presenta-
tion of neuropathic pain includes hyperalgesia, allodynia,
and spontaneous pain [1]. Its high prevalence in humans
[2-4] has led to the development of a number of animal
models of neuropathic pain, including diabetic periph-
eral neuropathy and spinal nerve ligation.
Changes within the nervous system associated with
neuropathic pain include critical upregulation of the
calcium channel subunit CaVa2δ-1 [5-7], particularly at
the dorsal horn [8,9]. This is of importance for the clini-
cal utility and potential mechanism of two different
pharmacotherapies, gabapentin and pregabalin, both of
which are indicated for the management of neuropathic
pain due to multiple etiologies. There is uncertainty
about the anatomical location of pregabalin’s beneficial
effect, as CaVa2δ-1 subunit upregulation is multifocal
[ 1 0 ] .I na d d i t i o nt ot h ek n o w ne x p r e s s i o nw i t h i nt h e
DRG, CACNA2D1 mRNA is also localized to brain
regions known to be involved in cortical processing,
sensory conduction, and arousal [11]. Also, there is also
marked CaVa2δ-1 subunit expression in spinal cord
regions where DRG projections occur. As a result, the
localization of pregabalin’s greatest therapeutic effect is
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changes in voltage gated channels [12-14] and micro-
gliosis with associated elevation in cytokines may occur
[15-18].
Pregabalin, as with gabapentin, interacts specifically
with the CaVa2δ-1 subunit of voltage-gated calcium
channels [19-21] providing an antihyperalgesic and anti-
allodynic effect specific for its action at the CaVa2δ-1
subunit [22]. Recently, Bauer et al [23] demonstrated
the importance of trafficking of the CaVa2δ-1 subunit
from the dorsal root ganglia to the dorsal horn in the
development of neuropathic pain, with its subsequent
alleviation with pregabalint r e a t m e n t .I nt h ep r e s e n t
study, we attempted to determine the central and per-
ipheral contributions of pregabalin for relief from neuro-
pathic pain in two separate models: streptozotocin-
induced diabetic peripheral neuropathy and traumatic
injury (spinal nerve ligation). We also examined the
therapeutic potential for intranasal delivery of pregabalin
with comparison to more localized delivery systems
using implantable pump systems permitting a continu-
ous delivery of pregabalin to specific anatomical loca-
tions [10,24]. Intranasal delivery, first developed to
bypass the blood-brain-barrier and directly target thera-
peutic agents to the central nervous system [25-28] of
rodents [29-31] and humans [30,31], occurs along both
the olfactory and trigeminal neural pathways using
extracellular pathways rather than axonal transport [30].
Such directed targeting of pregabalin to the brain can
avoid gastrointestinal uptake of oral therapy and may
permit more potent relief of neuropathic pain behavior
while limiting systemic side effects. For neuroinflamma-
tory, neurodegenerative, and neurovascular disorders
[28], intranasal delivery is an attractive non-invasive
method to target molecules to the central nervous sys-
tem [32,33] and even the peripheral nervous system
[34].
Our primary objective was to study the central deliv-
ery of pregabalin using either intranasal or intrathecal
therapy and compare to near-nerve delivery for impact
upon neuropathic pain behaviors. Previously, intranasal
delivery targeting the central nervous system has been
used as a method of delivery for neuropathic pain states
[34-36]. Intranasal delivery is dependent upon the olfac-
tory and trigeminal nerves connecting the nose to the
brain, the rostral migratory stream, and less so upon
vasculature and lymphatic pathways [28,37]. The benefit
of intranasal delivery is the concentration of effect in
the central nervous system; systemic delivery to some
extent will occur with small, lipophilic molecules deliv-
ered intranasally but is otherwise quite limited [28]. A
small, lipophilic molecule such as pregabalin would be
anticipated to have greater systemic distribution follow-
ing intranasal delivery than other compounds [38].
Rarely used in human clinical management at present
[35], the non-invasive nature of intranasal delivery along
with limited systemic exposure make it potentially
attractive for use in the clinic with human patients.
Intrathecal delivery of compounds with various mechan-
isms [10,39,40] has also led to amelioration of neuro-
pathic pain states. Already used in the clinic for delivery
of opioids, baclofen and conotoxins, intrathecal delivery
is an invasive technique used in specific situations of
refractoriness or intolerance of oral delivery, but its use
depends upon the agent used, its site of action, and its
ability to cross the blood-brain barrier. Finally, near
nerve delivery has also been used to modulate sensory
nerve regeneration and impact upon pain behaviors
[24,41,42]. Our secondary objectives of this study were
to evaluate changes in expression of the CaVa2δ-1 subu-
nit in the dorsal spinal cord, DRG peripheral nerve and
brain, evaluate potential changes in other voltage-gated
calcium and sodium channels in the spinal cord, DRG
and nerve, evaluate for changes in accumulation of
microglia, and to evaluate the safety and tolerability of
pregabalin using the various delivery routes in rodents,
including the use of intranasal delivery. We also exam-
ined the previously demonstrated role of CaVa2δ-1 sub-
unit trafficking [23] in a dynamic and progressive model
of neuropathic pain, diabetic peripheral neuropathy. The
determination of impact of pregabalin upon the
CaVa2δ-1 subunit within nervous system tissues
depending upon the mode of delivery would assist in
the understanding of the pharmacological action of
pregabalin upon the CaVa2δ-1 subunit and its effects
upon pathways relevant in the development of neuro-
pathic pain.
Results
Radiolabelled Detection of Pregabalin Localization
At 73 hours of intrathecal or intranasal delivery, prega-
balin concentrations were detected throughout the ner-
vous system (Figure 1). Intranasal delivery gave
consistently higher elevated pregabalin levels throughout
the central nervous system structures at and above the
cephalad portion of the cervical spinal cord. In contrast,
intrathecal delivery was associated with higher pregaba-
lin penetration into the lumbar spinal cord and much
higher levels within lumbar dorsal root ganglia. Systemic
presence of pregabalin was much higher at 73 hours
with intranasal pregabalin delivery, but was similar to
concentrations achieved with intrathecal delivery at 74
and 77 hours.
After 74 hours of chronic delivery, concentrations
with intranasally delivered pregabalin began to fall while
intrathecal levels were remaining stable throughout the
nervous system and systemically (Additional File 1). At
77 hours after intranasal delivery, both systemic and
Martinez et al. Molecular Pain 2012, 8:3
http://www.molecularpain.com/content/8/1/3
Page 2 of 20Intranasal and Intrathecal Pregabalin Delivery 
7
6
4
6
4
8
1
8
8
9
1
8
2
5
1
Near Nerve Pregabalin
Intrathecal Pregabalin
 Intranasal Pregabalin
Intrathecal Pregabalin
 Intranasal Pregabalin
Intrathecal Pregabalin
 Intranasal Pregabalin
Blood
Superficial Lymph
Nodes
Cervical Lymph Nodes
Quadriceps Muscle
Kidney
Liver
Lung
Urine
Olfactory Bulb
Frontal Cortex
Caudate Putamen
Parietal Cortex
Temporal Cortex
Hippocampus
Thalamus
Hypothalamus
Medulla
Ventral Cervical
Dura
Dorsal Cervical
Dura
Cephalad Cervical Cord
Caudal Cervical Cord
Mid-Thoracic Cord
Lumbar Cord
L5 Dorsal Root Ganglia
Proximal Sciatic Nerve
Cerebellum
Anterior Olfactory Nucleus
Septal Nucleus
Midbrain
Pons
* p<0.05
* p<0.05
* p<0.05
Ω
Ω p<0.05
* *
*
*
*
*
*
*
*
* *
*
*
*
* *
*
*
*
*
*
0
10
20
30
n
g
/
k
g
D
0
5
10
15
n
g
/
k
g
F
0
30
20
10
n
g
/
k
g
E
Intrathecal Pregabalin
 Intranasal Pregabalin
*
*
*
**
*
2
8
2
* p<0.05
0
10
20
30
n
g
/
k
g
A
Blood
Superficial Lymph
Nodes
Cervical Lymph Nodes
Quadriceps Muscle
Kidney
Liver
Lung
Urine
Intrathecal Pregabalin
 Intranasal Pregabalin
Olfactory Bulb
Frontal Cortex
Caudate Putamen
Parietal Cortex
Temporal Cortex
Hippocampus
Thalamus
Hypothalamus
Pons
Medulla
Cerebellum
Anterior Olfactory Nucleus
Septal Nucleus
Midbrain 0
60
40
20
n
g
/
k
g
B
* p<0.05
*
*
* *
*
* *
*
*
*
* *
*
*
6
9
1
6
7
2
2
7
0
1
Near Nerve Pregabalin
Intrathecal Pregabalin
 Intranasal Pregabalin
Ventral Cervical
Dura
Dorsal Cervical
Dura
Cephalad Cervical Cord
Caudal Cervical Cord
Mid-Thoracic Cord
Lumbar Cord
L5 Dorsal Root Ganglia
Proximal Sciatic Nerve 0
10
20
30
n
g
/
k
g
C
* p<0.05
*
*
*
*
*
Ω p<0.05
Ω
After One-Two Hours After Five Hours
Figure 1 Radiolabelled pregabalin detection. The harvested tissues are displayed on the X axis for the systemic (A, D) and for nervous system
tissues (B, C, E, F). Systemic (A) or nervous system (B, C) pregabalin concentrations are demonstrated for 73-74 hours after intrathecal (white
bars) or intranasal (black bars) or near nerve (gray bars) pregabalin delivery. Note that the 73 and 74 hour timepoints were analyzed together for
these timepoints early after completion of 72 hours of delivery. At 77 hours, at 5 hours after the most recent intranasal delivery, systemic (D),
brain (E), and cord (F) pregabalin concentrations started to fall. Near nerve delivery led to sciatic nerve pregabalin concentrations several fold
higher than achieved with either intrathecal or intranasal delivery, but near nerve delivery was not associated with detectable pregabalin
elsewhere. Significant differences between concentrations achieved with intervention methods were determined by matched ANOVA testing,
with * indicating significant differences (p < 0.05) between the intranasal or intrathecal pregabalin delivery and saline delivery techniques for
each tissue and respective delivery method. The doses provided through either intranasal or intrathecal delivery were selected to be similar to
doses of pregabalin used in later subexperiments [n = 4-6 rats in each rat cohort for each time point]. Note that data are not shown for
locations other than the sciatic nerve for near nerve pregabalin delivery, as other locations had no measureable pregabalin found.
Martinez et al. Molecular Pain 2012, 8:3
http://www.molecularpain.com/content/8/1/3
Page 3 of 20nervous system levels of intranasally delivered pregaba-
lin began to fall while intrathecal dosing provided rela-
tively stable pregabalin concentrations.
Near nerve delivery of pregabalin only led to detection
at the proximal sciatic nerve, with zero detection of
meaningful radioactive pregabalin at other systemic or
nervous system sites. The concentrations of pregabalin
received at the proximal sciatic nerve were several fold
higher with near nerve delivery than could be achieved
with intrathecal or intranasal delivery (Figure 1).
Maintenance of Diabetes in the Diabetic Peripheral
Neuropathy Model
After streptozotocin injection, rats developed diabetes
within 1 week in greater than 80% of animals, and in
each case, diabetes was maintained over the length of
the study. Diabetic rats were smaller than non-diabetic
rats at endpoint (201.8 ± 14.7 grams as compared to
234.5 ± 15.2 grams). Diabetic rat glycemia was increased
as compared to non-diabetic rats at endpoint (26.4 ± 3.1
mmol/L as compared to 6.1 ± 2.2 mmol/L).
Neuropathic Pain Behavior
Despite different methods and dosing of pregabalin
delivery, there was no impact upon locomotor function-
ing in rat cohorts studied with Rotarod testing at 72-74
hours post-pregabalin delivery (data not shown). Dia-
betic rats and rats subjected to spinal nerve ligation
both developed tactile allodynia and thermal hyperalge-
sia during experimentation (Figure 2). Both intrathecal
and intranasal pregabalin provision led to improvement
in tactile allodynia and thermal hyperalgesia at high
doses (2.04 mg/kg/d) in both diabetic peripheral neuro-
pathy and spinal nerve ligation models. Medium (0.51
mg/kg/d) doses of pregabalin decreased thermal hyperal-
gesia due to diabetic peripheral neuropathy and spinal
nerve ligation without impact upon tactile allodynia.
Lower doses (0.051 mg/kg/d) of intrathecal or intranasal
pregabalin had no impact upon either tactile allodynia
or thermal hyperalgesia in either model. Near-nerve
delivery of pregabalin had no impact upon tactile allody-
nia or thermal hyperalgesia with any dose (data not
shown) in either model of neuropathic pain.
mRNA Expression for CACNA2D1 and Other Voltage Gated
Channels in Diabetic Peripheral Neuropathy
Both diabetic peripheral neuropathy and spinal nerve
ligation were associated with elevation of CACNA2D1
mRNA expression within both the DRG and dorsal
spinal cord (Figure 3). However, there was no observed
impact of pregabalin delivery upon CACNA2D1 mRNA
expression within either location when compared to sal-
ine delivery in either model.
Protein Expression for a2δ-1 and other Voltage Gated
Channels
Immunohistochemical detection of CaVa2δ-1 protein in
nerves exposed to diabetes or spinal nerve ligation
demonstrated an increased number of CaVa2δ-1 posi-
tive profiles near the site of spinal nerve ligation, but
without impact of pregabalin delivery, irrespective of
site of delivery (Additional File 2). The presence of dia-
betes or the provision of spinal nerve ligation was also
associated with a shift to a greater number of CaVa2δ-1
positive DRG neurons within the DRG, but again there
was no impact with delivery of pregabalin regardless of
method of delivery or form of neuropathic pain (Addi-
tional File 2). Both diabetes and spinal nerve ligation led
to greater expression of CaVa2δ-1 protein at the dorsal
horn; at this location, however, receipt of high dose
pregabalin via intrathecal or intranasal delivery was
associated with relatively diminished expression of
CaVa2δ-1 protein (Figure 4) at the dorsal horn.
Dorsal spinal cord protein expression revealed by Wes-
tern blotting for CaVa2δ-1 protein was elevated in the
presence of diabetes or after spinal nerve ligation (Figure
5). In either model of neuropathic pain, delivery of
intranasal or intrathecal high dose pregabalin was asso-
ciated with less significant elevation of CaVa2δ-1 pro-
tein at the dorsal horn; meanwhile, near-nerve
pregabalin delivery had no impact upon dorsal horn
expression of CaVa2δ-1 protein. Similarly, diabetes and
spinal nerve ligation led to elevation of CaVa2δ-1 pro-
tein at the dorsal root ganglia, greatest in smaller noci-
ceptive neurons. However, no method of pregabalin
delivery impacted upon CaVa2δ-1 cellular or axonal pat-
terns of expression in the dorsal root ganglia or in per-
ipheral nerve (Additional Files 2, 3).
CaVa2δ-1 protein in the thalamus and primary sen-
sory cortex of the brain from rats exposed to diabetic
peripheral neuropathy, as well as in the contralateral
thalamus and primary sensory cortex, was unchanged in
the presence of neuropathic pain when compared to
control rats without diabetes or traumatic nerve injury
(Additional File 4).
Development of Increased Microglial Density and Activation
in Diabetic Peripheral Neuropathy
Microglial quantification was performed in the dorsal
thoracic and lumbar spinal cords in rats subjected to
diabetes and spinal nerve ligation. There was an
increased density of activated microglia in the dorsal
spinal cord regions in rats in either neuropathic pain
model when compared to control rat spinal cord speci-
mens (Figure 6). There was no difference in microglial
quantification in rats receiving saline or pregabalin with
any method of delivery in either model of neuropathic
pain.
Verification of Anterograde Trafficking of CaVa2δ-1 in
Dorsal Root Ligation and Spinal Nerve Ligation
For rats undergoing spinal nerve ligation +/- dorsal root
ligation, immunohistochemistry identified accumulation
of CaVa2δ-1 at sites proximal to the ligatures placed at
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Figure 2 Behavioral testing results for both models of neuropathic pain. Tactile (A) and thermal (B) sensory testing data for rats with or
without (control) diabetes and diabetic peripheral neuropathy (DPN) receiving intranasal pregabalin are presented for multiple doses of
pregabalin or saline. Intrathecal pregabalin delivery was also followed by measurements of tactile allodynia (C) and thermal hyperalgesia in
diabetic rats (D). High doses of either intranasal or intrathecal pregabalin impacted upon these neuropathic pain behaviours in DPN. For rats
with or without spinal nerve ligation receiving intranasal pregabalin, tactile (E) and thermal (F) sensory testing data are presented; intranasal
pregabalin at high dose impacted upon both measures of neuropathic pain behaviour. Finally, intrathecal pregabalin also impacted upon both
tactile allodynia (G) and thermal hyperalgesia (H) due to spinal nerve ligation when compared to saline delivery. Significant differences were
detected between the diabetic rats receiving high dose (2.04 mg/kg/d) (*) and medium dose (0.51 mg/kg/d) (θ) pregabalin as compared to
diabetic rats receiving saline delivery (non-matched ANOVA tests, F-values range between 1.98-22.86 for indicated groups and time points, n ≥ 5,
p < 0.0125 after Bonferroni correction). Significant differences were detected between rats with spinal nerve ligation receiving high dose (2.04
mg/kg/d) (*) and medium dose (0.51 mg/kg/d) (θ) pregabalin as compared to rats with spinal nerve ligation receiving saline delivery (non-
matched ANOVA tests, F-values range between 2.25-8.11 for indicated groups and time points, n ≥ 5, p < 0.0125 after Bonferroni correction) [n
= 5-6 rats in each cohort for each time point]. Data for rats receiving low dose pregabalin were similar to data for rats receiving saline and are
not shown.
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cedures were performed (Figure 7). Dorsal horn expres-
sion of CaVa2δ-1 was elevated with
immunohistochemistry or with Western blotting with
the absence of dorsal root ligation regardless of delivery
of intrathecal pregabalin or saline; however, CaVa2δ-1
protein levels at the dorsal horn were suppressed in the
presence of a dorsal root ligature. When dorsal root
ligature was present, CaVa2δ-1 protein accumulation
occurred at the portion of dorsal root distal (but not
proximal) to dorsal root ligature, with partial suppres-
sion due to intrathecal pregabalin delivery. At the spinal
root, the presence or absence of spinal nerve ligation
did not influence expression of CaVa2δ-1 protein. These
findings demonstrate the anterograde transport of
CaVa2δ-1 protein away from the dorsal root ganglia
after traumatic nerve injury.
Discussion
Sufficient doses of pregabalin provided through intrana-
sal or intrathecal methods ameliorated tactile allodynia
and thermal hypersensitivity due to spinal nerve ligation
or diabetic peripheral neuropathy, but there was no ben-
efit of providing pregabalin at the level of the peripheral
nerve in either condition, suggesting that pregabalin’s
benefit is localized to the dorsal root ganglia or its cen-
tral projections. In particular, pregabalin provision intra-
nasally or intrathecally led to partial reversal of
upregulation of CaVa2δ-1 at the pre-synaptic nerve
terminals in the dorsal horn of the spinal cord [7,8].
This may relate to postulated central trafficking of the
CaVa2δ-1 subunit from the dorsal root ganglia [23], and
its potential block with pregabalin [23]. Pregabalin’s
effect appeared to be limited to impact upon trafficking
of CaVa2δ-1 protein away from the dorsal root ganglia
centrally.
Voltage-gated calcium channels are heterogenous mul-
timeric complexes composed of several different subu-
nits including a1, b, a2δ,a n dg [43,44]. The CaVa2δ-1
subunit is an auxiliary subunit which facilitates targeting
and assembly of channels at the cell surface [45]. CAC-
NA2D1 is transcribed as a single mRNA from a single
gene, with the translated CaVa2δ-1 subunit protein
cleaved to yield a2 and δ proteins; these are subse-
quently disulfide-linked and glycosylated, leading to
functional CaVa2δ-1 subunits [46]. There are four dif-
ferent CaVa2δ-1 subunits: the CaVa2δ-1 subunit has
been investigated most, due to its ability to serve as a
ligand for the gabapentinoids [19]. Expression of
CaVa2δ-1 in normal situations is essentially confined to
neurons withn the brain, spinal cord, and DRG [11]. In
the brain, CACNA2D1 mRNA is localized to regions
important for cortical processing, primary sensory trans-
mission, and arousal; however, we discovered no mea-
surable changes in CaVa2δ-1 protein expression in the
neuropathic pain states studied, regardless of mode of
pregabalin delivery. Instead, the observed changes in
CaVa2δ-1 protein expression at the dorsal horn appear
to be of greater importance.
Upregulation of CaVa2δ-1 in the spinal cord is essen-
tial for both initiation and maintenance of neuropathic
pain in many conditions [47]. Although upregulation of
CaVa2δ-1 occurred in the DRG and at the dorsal root
as well, there was no impact of pregabalin upon
CaVa2δ-1 protein levels at these locations. In addition,
elevation of CACNA2D1 mRNA in neuropathic pain
states at the dorsal horn and dorsal root ganglia was not
impacted by forms of pregabalin delivery. The isolated
Figure 3 Expression of CACNA2D1 mRNA. Expression of
CACNA2D1 mRNA was upregulated in both dorsal spinal cord (A)
and lumbar DRGs (B) in the presence of either diabetic peripheral
neuropathy (DPN) or spinal nerve ligation (SNL). Dorsal horn mRNA
expression was unchanged by presence of high dose pregabalin
(2.04 mg/kg/d) provided either through intrathecal or intranasal
delivery when compared to saline delivery (A). There was no impact
of pregabalin delivered in any manner upon mRNA expression in
lumbar DRGs when compared to saline delivery, although the
presence of spinal nerve ligation or diabetic peripheral neuropathy
was associated with elevated CACNA2D1 mRNA expression when
compared to control rat specimens (B), indicated by the * above
the Control rat data (non-matched ANOVA tests, F-values range
between 0.42-1.00 for indicated groups and time points, n ≥ 3, * p
< 0.0125) [n = 6-8 specimens for each cohort].
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Page 6 of 20Figure 4 CaVa2δ-1 protein expression. CaVa2δ-1 protein expression was detected by immunohistochemistry at the dorsal horn regions of rats
subjected to spinal nerve ligation or diabetes (A). Rats exposed to high dose (2.04 mg/kg/d) pregabalin provided intrathecally or intranasally had
less expression of CaVa2δ-1 at the dorsal horn as compared to rats receiving near-nerve delivery of pregabalin or with saline delivery for both
models of diabetic peripheral neuropathy (DPN) (B) and spinal nerve ligation (SNL) (C). As compared to control rat specimens, the presence of
either spinal nerve ligation or diabetes uniformly led to upregulation of CaVa2δ-1 at the dorsal horn. Unmatched ANOVA tests were performed
between cohorts receiving pregabalin and saline for each intervention and condition, and between intervention locations, with * indicating
significant difference (p < 0.0125 after Bonferroni corrections) between cohorts [n = 3-5 specimens for each cohort].
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1 protein levels at the dorsal horn suggests a pregabalin-
mediated prevention of an anterograde trafficking pro-
cess [23]. However, no such distal anterograde traffick-
ing of CaVa2δ-1 protein towards the periphery could be
detected, and there was no accumulation of CaVa2δ-1
protein at the spinal nerve ligation as occurred at the
ligature around the dorsal nerve root. The presence of a
dorsal root ligature prevented the upregulation of
CaVa2δ-1 protein levels at the dorsal horn, leading to
accumulation of CaVa2δ-1 protein proximal to the dor-
sal root ligature, implicating CaVa2δ-1 protein
Figure 5 Protein Quantification. Western blotting identified increased levels of CaVa2δ-1 protein in the dorsal horn and lumbar DRGs for rats
exposed to either diabetic peripheral neuropathy (DPN) or spinal nerve ligation (SNL) when compared to control rats (A). In the dorsal spinal
cord, either intrathecal or intranasal delivery of high dose (2.04 mg/kg/d) pregabalin was associated with less upregulation of CaVa2δ-1 protein
than with saline delivery (B). The near nerve delivery of pregabalin failed to impact upon CaVa2δ-1 protein expression in the dorsal spinal cord
following SNL or DPN (A, B). Finally, pregabalin delivered in any manner was not associated with impact upon CaVa2δ-1 protein expression in
the lumbar DRGs exposed to either DPN or SNL when compared to saline delivery (intrathecal delivery results shown) (A). Multiple unmatched
ANOVA tests were performed between cohorts receiving pregabalin and saline for each intervention and condition, with * indicating significant
difference (p < 0.0125 after Bonferroni corrections) between cohorts. b-actin protein levels were used for quantification of ratios of CaVa2δ-1/b-
actin demonstrated in B.
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an important factor in establishment of neuropathic
pain, confirming the results of Bauer et al [23]. These
same unmyelinated DRG sensory neurons important for
nociception (unmyelinated C-fibers for transmission of
thermal hyperalgesia and large-diameter Aδ afferent
fibers for transmission of tactile allodynia [48,49])
synapse in laminae I and II of the dorsal horn or at Lis-
sauer’s tract. We determined that CaVa2δ-1 immunor-
eactivity was elevated unilaterally with spinal nerve
ligation and bilaterally with diabetic peripheral neuropa-
thy in the dorsal column at thoracolumbar levels above
the spinal nerve ligation injury, as well as in DRG neu-
rons [23]. Most importantly, decreases in CaVa2δ-1
immunoreactivity at the dorsal horn were associated
with successful analgesia of neuropathic pain with preg-
abalin. As a result, we hypothesize that pregabalin acts
to slow or prevent the trafficking of the CaVa2δ-1 pro-
tein from the dorsal root ganglia to the dorsal horn.
The upregulation of CaVa2δ-1 within the spinal
cord leads to increased presynaptic Ca
2+ influx as well
as neurotransmitter release, contributing to sensitiza-
tion and neuropathic pain [50]. In models of neuro-
pathic pain, the gabapentinoids gabapentin and
pregabalin reduce neurotransmitter release and excita-
tory synaptic transmission at the spinal cord [51,52].
Controversies regarding the mechanism of action of
the gabapentinoids have occurred, with some studies
demonstrating no acute effects of gabapentin upon
spontaneous synaptic currents in lamina II neurons
[53], while other studies have shown gabapentin’sa b i l -
ity to reduce both inhibitory and excitatory neuro-
transmission at the dorsal horn by preferentially
blocking only P/Q-type Ca
2+ channels [54] and
through prevention of intracellular endosome recy-
cling of CaVa2δ-1 protein [55]. There has been no
effect upon the levels of CaVa2δ-1 protein or CAC-
NA2D1 mRNA elsewhere, though, such as at the DRG
(despite the presence of all three CaVa2δ subunits at
t h eD R G )[ 1 1 ]a n di nt h ep e r i p h e r a ln e r v e .T h i sm a y
signify that trafficking, but not expression or endocy-
tosis, of CaVa2δ-1 from DRG to presynaptic terminals
is impacted upon by pregabalin [23]. Other potential
mechanisms for gabapentinoids include a more acute
inhibitory effect upon neurotransmitter release [56]
which may relate to upregulation of protein kinase C
activation [57,58].
Chronic, and not acute, pregabalin delivery reduces
the neuronal expression of CaVa2δ-1 in vitro without
impact upon constitutive endocytosis, leading to high
levels of CaVa2δ-1 being present in intracellular vesicles
[23]. This effect may be a consequence of calcium chan-
nel trafficking through the Von Willebrand factor-A
domain in the a2 subunit of CaVa2δ-1 [59], as well as
blocked CaVa2δ-1 trafficking [23,60]. Transgenic
mutants for CaVa2δ-1 unable to bind gabapentinoids
have reduced trafficking, supporting this hypothesis
[60,61]. This hypothesized mechanism of disrupted traf-
ficking would be unique, di s t i n c tf r o mt h a to fo t h e r
pharmacotherapies with a direct neuronal surface action,
and may relate to CaVa2δ-1 recycling at the endosome
[55]. We postulate that the effects of pregabalin upon
CaVa2δ-1 trafficking occurs peripherally, either at the
dorsal root ganglia or the dorsal root.
There was no measureable impact of pregabalin deliv-
ered by any method upon the activation and accumula-
tion of microglia in the spinal cord either. Ectopic
activity contributing to sensitization due to excessive
activity in voltage-gated calcium channels and voltage-
gated sodium channel may occur within both A or C
fibres [62-64], relating to neuronal hyperexcitability [14].
Microglia and their activation, leading to cytokine pro-
duction important in neuropathic pain, are apparent and
play a key role in pathophysiological pain due to both
nerve injury [15-17] and diabetes [18]. Pregabalin’s lack
of impact upon these other established mechanisms for
induction of neuropathic pain suggest its specificity at
the CaVa2δ-1 subunit of the voltage-dependent calcium
channel. However, other pathological changes associated
with neuropathic pain continue abated despite pregaba-
lin delivery.
Figure 6 Microglia Assessment. Microglia accumulation was
assessed in the dorsal regions of thoracic and lumbar spinal cord
for control rat spinal cord (A), and with either spinal nerve ligation
(B) or diabetic peripheral neuropathy (C) in rats. Greater
immunohistochemically-identified accumulation and activation of
microglia in the dorsal spinal cord of rats was seen with spinal
nerve ligation or diabetic peripheral neuropathy (D) without impact
of pregabalin delivery.* indicates significant differences between
control (sham SNL surgery or citrate-injected non-diabetic rat
respectively) and all SNL and DPN rat values using individual
unmatched ANOVA testing (p < 0.0125 after Bonferroni corrections).
Bar = 50 μm.
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Page 9 of 20Figure 7 Dorsal and Spinal Root Ligation Experiments. A cartoon diagram of the procedures performed in spinal nerve ligation and dorsal
root ligation is provided. Tissues obtained after 7 days of spinal nerve ligation and/or dorsal root ligation (or neither in control rats) were
examined using immunohistochemistry for CaVa2δ-1 protein and with Western blotting for CaVa2δ-1 protein and b-actin, used as a loading
control. At the level of the dorsal horn (1), the presence of a dorsal root ligature prevented upregulation of CaVa2δ-1 protein regardless of
delivery of intrathecal pregabalin or intrathecal saline. At the dorsal root proximal to dorsal root ligature (2), there was a similar lack of
upregulation of CaVa2δ-1 protein regardless of delivery of intrathecal pregabalin or intrathecal saline, unless dorsal root ligature was absent. At
the level of the dorsal root distal to spinal nerve ligation (3), there was an accumulation of CaVa2δ-1 protein, with less significant CaVa2δ-1
protein expression when intrathecal pregabalin was delivered or if spinal nerve ligation was absent. Distal to the dorsal root ganglia and
proximal to spinal nerve ligation (4) or at the spinal root distal to spinal nerve ligation (5), there was no change in expression of CaVa2δ-1
protein irregardless of delivery of intrathecal pregabalin or intrathecal saline, or even if spinal nerve ligation was absent. Multiple unmatched
ANOVA tests were performed between cohorts receiving intrathecal pregabalin and saline as compared to control rat samples and samples
without placement of either spinal or dorsal root ligatures, with * indicating significant difference (p < 0.017 after Bonferroni corrections)
between cohorts. Bars = 10 μm.
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require discussion. There is overlap between the tissues
that receive pregabalin from intranasal and intrathecal
delivery-it is probable that both forms of delivery
impacted upon the dorsal horn region, but there may
have been some undefined impact of intranasal prega-
balin delivery at supraspinal locations as well (even
with the lack of impact upon CaVa2δ-1 expression in
brain). The absence of heightened CaVa2δ-1 expression
at the supraspinal locations does not exclude the possi-
bility of pregabalin possessing a role in supraspinal
pain processing-it is possible that pregabalin may have
important effects at the medulla and cortex [65-68];
this may explain the effects of intranasal pregabalin
delivery, which only resulted in small concentrations of
pregabalin in the lumbar spinal cord and dorsal root
ganglia. Pregabalin’s effects within the cerebrum may
be contributory, especially after demonstrations of high
cerebral concentratons of pregabalin following its intra-
nasal delivery. Although we did not demonstrate
impact of forms of delivery of pregabalin upon micro-
glia accumulation in the spinal cord, it is possible that
a longer duration of pregabalin delivery, or earlier
onset of pregabalin delivery, is required before an anti-
neuroinflammatory effect m a yb ed e m o n s t r a t e d ,a s
shown in prior studies [36,69,70]. For example, in a
model of diabetic peripheral neuropathy with daily
gabapentin delivery over 5 days followed by immediate
tissue harvesting, amelioration of spinal microglial acti-
vation occurred [71]. The levels of pregabalin achieved
within the lumbar spinal cord and dorsal root ganglia
were measured to be low after 74 hours-we hypothesize
that pregabalin’s effects may be summated over time
rather than related to an absolute concentration
achieved at one time point, although we cannot verify
this. We did not study a systemic application such as
with gastric/oral or intravenous forms of delivery due
to the more widespread distribution of gabepentinoids
with these methods and the presence of prior data
assessing these delivery methods [72,73]. The timing of
pregabalin/saline delivery in the spinal nerve ligation
experiments was initiated 7 days after the spinal nerve
ligation occurred in order to provide intervention dur-
ing the time of greatest neuropathic pain behavior;
however, we selected the first 7 days after double liga-
tion to study CACNA2D1 mRNA and CaVa2δ-1 pro-
tein expression during the time period of neuropathic
pain behavior initiation-this difference in timing may
have led to inconsistencies in molecular test results.
Although we, and others [23], have hypothesized that
pregabalin’s mechanism of action is the disruption of
CaVa2δ-1 trafficking, it remains unclear why expres-
sion of CACNA2D1 mRNA and CaVa2δ-1 protein is
unaffected at the dorsal root ganglia. Together, these
findings suggest that pregabalin’sa c t i o ni si n d e p e n d e n t
of translation of CaVa2δ-1 or transcription of CAC-
NA2D1. As well, it would be anticipated that disrupted
trafficking of CaVa2δ-1 would result in CaVa2δ-1
upregulation at the dorsal root ganglia, but this was
not identified. However, pregabalin-mediated effects
u p o nt h ep r e s e n c eo fC a V a2δ-1 protein at the more
proximal spinal nerve root and dorsal horn is indicative
of pregabalin-induced suppression of the central traf-
ficking of CaVa2δ-1 protein, as previously identified
[23]. Rats received isoflurane anesthesia prior to intra-
nasal delivery, but were tested for neuropathic pain at
times that were many half lives after isoflurane discon-
tinuation to avoid anesthetic effects upon behavioural
testing. Finally, we designed this study to compare dif-
ferent modes of delivery of pregabalin upon neuro-
pathic pain behaviours; however, our results cannot be
used to interpret the site of action of pregabalin due to
significant overlap in pregabalin’s anatomical destina-
tions with the intranasal and intrathecal delivery
modes. However, we propose that a non-invasive form
of pharmacologically targeting the dorsal horn and dor-
sal root ganglia, such as with intranasal delivery, may
be a consideration for the management of human neu-
ropathic pain.
Conclusions
The present data confirm the efficacy of pregabalin in
the modulation of acute thermal and tactile hypersensi-
tivity as features of neuropathic pain. The site of provi-
sion is critical, as exclusive delivery to the peripheral
nerve has no impact; only delivery using intranasal or
intrathecal delivery was associated with impact upon
neuropathic pain behaviours and molecular outcomes.
Furthermore, delivery using either intranasal or intrathe-
cal methods led to diminished CaVa2δ-1 expression at
the dorsal horn, suggesting that pregabalin inhibits cen-
tral trafficking of the CaVa2δ-1 subunit from the dorsal
root ganglia as previously shown by Bauer et al [23].
Future studies should examine the in vivo and in vitro
trafficking of CaVa2δ-1 and the mechanisms by which
pregabalin can influence the cell surface expression of
CaVa2δ-1; another gabapentinoid, gabapentin, has been
shown to prevent the recycling of the related protein
CaVa2δ-2 from endosomes and the subsequent insertion
in the plasma membrane without influencing internali-
zation of CaVa2δ-2 [55]. The different impacts of prega-
balin upon the central and peripheral axons of the
dorsal root ganglia neurons are not yet understood.
Finally, the intranasal delivery of agents such as prega-
balin in order to directly target the nervous system may
be a realistic method in managing neuropathic pain in
humans, and may assist in the avoidance of systemic
adverse effects.
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Animals
All experiments were carried out using male Sprague
Dawley rats (Charles River Laboratories), weighing 200-
225 grams at initiation. Protocols were reviewed and
approved by the University of Calgary Animal Care
Committee using the Canadian Council of Animal Care
guidelines. All attempts were made to minimize animal
numbers and to maintain ethical standards. Experimen-
tal study groups were randomized and behavioural stu-
dies were performed by an experimenter who was
unaware of treatment groups.
In all cases, rats were housed in plastic sawdust cov-
ered, pathogen-free cages with a normal light-dark cycle
and free access to chow and water. Rats were anesthe-
tized with pentobarbital (57 mg/kg) prior to all surgeries
and terminal endpoints, and with inhaled isoflurane pro-
vided for all intranasal delivery points.
Sample size calculations
A sample size calculation for intervention groups was
based upon an anticipated difference in neuropathic
pain behavioral changes observed in treated diabetic rats
to date, with an a of 0.05 and b of 0.5 providing a mini-
mal sample size of n = 5 within each intervention
group; this was increased to 6 rats due to anticipated
minimal diabetes-related mortality over the three week
study.
Radiolabeled Pregabalin Studies to Determine
Localization of Delivery
We performed radiolabelled studies to determine the
distribution of pregabalin reaching the central and per-
ipheral nervous system afteri n t r a n a s a lo ri n t r a t h e c a l
delivery. We examined the distribution of pregabalin at
1, 2, and 5 h after 72 hours of chronic delivery of intra-
nasal, intrathecal, or near nerve delivery. A combination
of
125I labeled pregabalin and unlabeled pregabalin was
delivered during studies at the Alzheimer’s Research
Center at Regions Hospital in St. Paul, MN, USA. This
procedure was approved by the Institutional Animal
Care and Use Committee at Regions Hospital. Prior to
experimentation, 30 diabetic rats (induced via streptozo-
tocin injections, described below) were sedated for intra-
nasal or intrathecal delivery using pentobarbital
anesthesia (60 mg/kg).
125I-labelled pregabalin was pro-
vided to 10 rats via intrathecal delivery, to 10 rats via
intranasal delivery, and to 10 rats via near nerve delivery
(see below for procedure descriptions). Pregabalin (Pfi-
zer Global, New York, New York) with an initial con-
centration 3.125 μg/μl was dissolved in PBS and custom
labeled with
125I (GE Healthcare, Piscataway, New Jer-
sey, USA). Synthesized radiolabelled pregabalin solution
contained 266.7 μCi/μg.
125I-labeled pregabalin delivery
(intranasal or intrathecal) was performed in a fume
hood behind a lead impregnated shield, with anesthe-
tized rats placed supine. A mixture of
125I pregabalin
(19.2 μCr) and unlabeled pregabalin (30.0 μg) were
administered intranasally or intrathecally.
125I pregabalin
was intranasally administered over alternating nares as
eight 6-μL drops with an Eppendorf pipetter every 2
minutes, for a total volume of 48 μL, provided twice
daily for 3 days prior to a single delivery on day 4 as per
a prior schedule [30]. For intrathecal delivery,
125Ip r e g -
abalin was delivered using a placed intrathecal catheter
(see below) attached to an Alzet pump (described
below) with delivery of 2.04 mg/kg/d over 72 hours con-
tinually delivering a mixture of
125I pregabalin (19.2
μCr) and unlabeled pregabalin (30.0 μg) over each 24
hour period for 73, 74 and 75 hours prior to harvesting.
For near nerve delivery,
125I pregabalin was delivered
using a placed T-chamber around the proximal sciatic
nerve (see below) attached to an Alzet pump (described
below) with delivery of 2.04 mg/kg/d over 72 hours con-
tinually delivering a mixture of
125I pregabalin (19.2
μCr) and unlabeled pregabalin (30.0 μg) over each 24
hour period for 73, 74 and 75 hours prior to harvesting.
Each desired dose contained a calculated radioactive
dose of 40 μCi per day to best provide concentrations
similar to the long-term duration experiments described
below.
At each of 1, 2, and 5 hours after 72 hours of initiat-
ing either
125I pregabalin intranasal delivery, intrathecal
or near-nerve delivery, cardiocentesis was performed for
blood extraction. Euthanasia was performed via trans-
cardial perfusion using 60 mL of saline, followed by 500
mL of 4% paraformaldehyde while the rat was main-
tained under anesthesia. To quantify
125I distribution,
blood, urine, lymphatic (superficial perimandibular
lymph nodes and cervical lymph nodes) and visceral
organ structures (quadriceps muscle, kidney, liver, and
lung), as well as portions of the central (olfactory bulb,
anterior olfactory cortex, frontal cortex, caudate puta-
men, parietal cortex, temporal cortex, hippocampus,
septum, thalamus, hypothalamus, midbrain, pons,
medulla, cerebellum, cephalad cervical spinal cord, cau-
dal spinal cord, mid-thoracic spinal cord, and lumbar
spinal cord) and peripheral nervous systems (fifth lum-
bar dorsal root ganglia and proximal sciatic nerve) and
associated tissues (ventral and dorsal cervical dura
mater) were harvested. Gamma signal was recorded for
each body region with autoradiographic imaging using a
COBRA II Auto-Gamma Counter (Perkin-Elmer, Wal-
tham, Mass., USA). Concentrations of
125I pregabalin
were calculated based upon the gamma counting data,
tissue weight, specific activity of the drug administered
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tration into peripheral and central nervous system
tissues.
To confirm patency and delivery with near-nerve
chamber placement, infusion pumps containing India
ink were implanted in four animals with pumps con-
nected to the nerve regeneration chamber (see below).
The presence of India ink was detected in all cases only
at the catheter site for days 3, 7, and 14. Pump and
catheter volume infusion rates were approximately 15 μl
per day, or approximately 200 μlo v e r1 4d a y sf o rt h i s
India Ink experiment.
Models of Neuropathic Pain
Diabetes and Diabetic Peripheral Neuropathy
At the age of 1 month, rats intended to be diabetic were
injected with streptozotocin diluted in sodium citratre
(pH 4.7, Sigma, St. Louis, MO) intraperitoneally once
daily for each of three consecutive days with doses of 60
mg/kg, 50 mg/kg, and then 40 mg/kg, while rats
intended to be non-diabetic were injected with volume-
matched carrier (sodium citrate pH 4.7) for three conse-
cutive days. Streptozotocin ablates pancreatic b cells
leading to an insulin deficient diabetic state. No insulin
treatment was used at any time during the protocol. In
all cases, whole blood glucose measurements were per-
formed using puncture of the tail vein and a blood gluc-
ometer (OneTouch Ultra Meter, LifeScan Canada,
Burnaby, BC, Canada). Hyperglycemia was verified 1
week after streptozotocin injections, with a fasting
whole-blood glucose level of ≥ 16 mmol/l (normal 5-8
mmol/l) being our definition for experimental diabetes.
Rats that did not meet these criteria for diagnosis of dia-
betes were excluded from further assessment. During
diabetes, daily inspection of footpads occurred to rule
out the presence of wounds or burns. No insulin or
other diabetes therapies were provided during these
investigations.
Spinal Nerve Ligation
Spinal nerve ligation was performed as described by Kim
and Chung [74]. Briefly, the right L5/6 lumbar spinal
nerves of male Sprague Dawley rats (200 g) were
exposed in isoflurane/oxygen-anesthetised rats followed
by tight ligation with 5.0 silk sutures between the DRG
and proximal to the junctions forming the sciatic nerve.
Sham operations were performed in the same way
except that spinal nerves were not ligated. The left
spinal nerves for all rats were left untouched.
Study Timelines, Animal Groups and Drug Administration
We conducted studies using the rat diabetic peripheral
neuropathy model. A total of 118 male Sprague Dawley
rats were induced diabetic while 26 male Sprague Daw-
ley rats were studied as citrate-injected control
littermates over the course of 3 weeks of diabetes with-
out delivery of any other therapeutic agents other than
pregabalin. Rates of conversion to diabetes were in
excess of 95%. These rats were accustomized and stu-
died with sensory behavioral testing every 3 days begin-
ning prior to streptozotocin injections. Of the 118 rats
receiving intraperitoneal streptozotocin injections, those
with confirmed diabetes status were randomized to one
of four varied dose groups within each of the interven-
tion groups: 1) intranasal delivery with low dose (0.051
mg/kg/d) pregabalin (n = 9), medium dose (0.51 mg/kg/
d) pregabalin (n = 8), or high dose (2.04 mg/kg/d) preg-
abalin (n = 8) or equal volumes of saline (n = 8); 2)
intrathecal delivery with low dose (0.051 mg/kg/d) preg-
abalin (n = 9), medium dose (0.51 mg/kg/d) pregabalin
(n = 8), or high dose (2.04 mg/kg/d) pregabalin (n = 8)
or equal volumes of saline (n = 8); 3) near-nerve deliv-
ery with low dose (0.051 mg/kg/d) pregabalin (n = 9),
medium dose (0.51 mg/kg/d) pregabalin (n = 8), or high
dose (2.04 mg/kg/d) pregabalin (n = 8) or equal volumes
of saline (n = 9). Those receiving intraperitoneal citrate
injections (non-diabetic rats) were divided into intrana-
sal (n = 7), intrathecal (n = 6) or near-nerve (n = 7)
intervention groups. Following 7 days after diabetes con-
firmation occurred, intranasal, intrathecal, or near-nerve
delivery began and occurred for a total of 14 continuous
days. Neuropathic pain behaviors typically initiate within
the first week after streptozotocin-induced diabetes con-
firmation [75], with initiation of interventions occurring
2 weeks after completion of streptozotocin injections.
We examined a model of traumatic neuropathy, the
rodent spinal nerve ligation model. A total of 93 male
Sprague Dawley rats received the spinal nerve ligation
procedure while 23 male Sprague Dawley rats were stu-
died as sham-operated control littermates. These rats
were studied with sensory behavioral testing every 3
days beginning prior to spinal nerve ligation or sham
procedure. The 93 rats receiving spinal nerve ligation
were randomized to one of four varied dose groups
within each of the intervention groups: 1) intranasal
delivery with low dose (0.051 mg/kg/d) pregabalin (n =
7), medium dose (0.51 mg/kg/d) pregabalin (n = 6), or
high dose (2.04 mg/kg/d) pregabalin (n = 6) or equal
volumes of saline (n = 6); 2) intrathecal delivery with
low dose (0.051 mg/kg/d) pregabalin (n = 7), medium
dose (0.51 mg/kg/d) pregabalin (n = 6), or high dose
(2.04 mg/kg/d) pregabalin (n = 6) or equal volumes of
saline (n = 6); 3) near-nerve delivery with low dose
(0.051 mg/kg/d) pregabalin (n = 7), medium dose (0.51
mg/kg/d) pregabalin (n = 6), or high dose (2.04 mg/kg/
d) pregabalin (n = 6) or equal volumes of saline (n = 6).
Those rats receiving sham procedures were divided into
intranasal (n = 7), intrathecal (n = 7) or near-nerve (n =
6) intervention groups. Following 7 days after spinal
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nerve delivery began and occurred for a total of 14 con-
tinuous days. It has been demonstrated that spinal nerve
ligation results in osnet of neuropathic pain behaviors in
the first 1-7 days after spinal nerve injury [76].
Intranasal, Intrathecal and Near-Nerve Delivery Systems
Doses of pregabalin were selected based upon prior
delivery of intrathecal gabapentin, a molecule similar to
pregabalin but with less potency for the a2δ-1 subunit
of voltage dependent calcium channels [52]. Intranasal
pregabalin or saline delivery occurred twice daily during
periods of therapy. Isoflurane-anesthetized rats were
placed on their back with necks held in extension for
intranasal administration, administered twice daily as
ten 8 μl drops for a total volume of 80 μl for each nare,
with delivery to alternating nares with 1-2 minutes
between drops (i.e., ten drops per nare), for a total of
320 μl per day. Intrathecal delivery of pregabalin or sal-
ine occurred through Alzet mini osmotic pumps provid-
ing a continuous delivery of pregabalin/saline at a rate
of 0.5 μl per hour. Near-nerve delivery of pregabalin or
saline also occurred through Alzet mini osmotic pumps
providing a continuous delivery of pregabalin/saline at a
rate of 0.5 μl per hour. In each case where pregabalin
was provided, there were three different total daily doses
(low dose (0.2 μmol or 0.051 mg/kg), medium dose (2.0
μmol or 0.51 mg/kg), or high dose (8.0 μmol or 2.04
mg/kg)) of pregabalin delivered for each of the interven-
tion systems.
For intrathecal delivery, we used the same surgical
exposure as performed for spinal nerve ligation/sham,
or created a new surgically exposed area over the right
L5/6 spinal nerve region for diabetic/non-diabetic rats
[10]. After incising the back skin at the lower lumbar
region, a subcutaneous pouch was created. A silicone
catheter (0.012 inches × 0.025 inches) was positioned
into the lumbar intrathecal space in the created pouch
between L6 and S1 vertebrae while connected to a two-
week Alzet mini-osmotic infusion pump placed in the
dorsal subcutaneous space of the rat. Alzet mini-osmotic
infusion pumps are easily inserted into the subcutaneous
space and require no external connections while provid-
ing a continuous, constant level of delivery to be pro-
vided over a two week period after placement. Surgical
closure with 9-0 silk suture was performed around the
subcutaneous pouch at the lumbar region. Surgeons
were blinded as to the contents of the infusion pumps
placed, which were randomized to either contain prega-
balin (low (0.051 mg/kg/d), medium (0.51 mg/kg/d) or
high dose (2.04 mg/kg/d)) or saline in a 3:1 ratio.
For near-nerve delivery, we used the same surgical
exposure as performed for spinal nerve ligation/sham,
or created a new surgically exposed area over the right
spinal nerve region for diabetic/non-diabetic rats [10].
After incising the back skin at the lower lumbar region,
a subcutaneous pouch was created. A two-week Alzet
mini-osmotic infusion pump is placed in the dorsal sub-
cutaneous pouch of the rodent. A nerve regeneration
chamber is placed to surround the spinal nerve ligation
site-the equipment used is composed of a 6.5 mm
length (modified from 10 mm to compensate for the
short distance of the spinal nerve) of silastic tubing
(size: 1.98 mm inside diameter × 3.18 mm outside dia-
meter; Dow Corning, Michigan). A small porthole cut
into the side of the nerve chamber permits access with
o n ee n do fas i l i c o n ec a t h e t e r ,w i t has m a l la m o u n to f
cyanoacrylate cement (Instant Krazy Glue; Advanced
Formula Gel; Elmer’s Products Canada, Brampton, Ont.)
placed at the outside of the end of the access tube
before inserting it into the porthole. A second silastic
tube (size: 0.76 mm inside diameter × 1.65 mm outside
diameter) permits connection of the silicone catheter to
the nerve regeneration chamber and Alzet pump on
either end. Before their use, the entire apparatus used is
autoclaved. Surgical closure with 9-0 silk suture was
performed around the subcutaneous pouch and at the
spinal nerve ligation exposure site. Surgeons were again
blinded as to the contents of the infusion pumps placed,
which were randomized to either contain pregabalin
(low (0.051 mg/kg/d), medium (0.51 mg/kg/d) or high
dose (2.04 mg/kg/d)) or saline in a 3:1 ratio.
During all intervention protocols, all animals were
monitored post-operatively for signs of infection or
other complications of surgery. For the purposes of data
demonstration, Day 1 is considered to be the last of 7
days after either diabetes confirmation (for diabetic per-
ipheral neuropathy studies) or 7 days after spinal nerve
ligation occurred-this is one day before the start of
interventions provided using intranasal, intrathecal, or
near-nerve delivery of doses of pregabalin or saline.
Note that after Day 15, no further intervention was pro-
vided prior to surgical harvesting on Day 18.
Sensory Behavioral Testing
In all cases, baseline testing was done beginning prior to
streptozotocin injections or spinal nerve ligation proce-
dure and ongoing testing continued until after pregaba-
lin or saline delivery was completed, occurring every 3
days. During maintenance therapy, behavioural testing
was performed at 2-4 hours after the morning dose of
intranasal pregabalin/saline administration was deliv-
ered, during the time in which pregabalin concentra-
tions were peaking in the nervous system. This latency
period between dosing and behaviour testing was neces-
sary to permit elimination of isoflurane anesthesia deliv-
ered during pregabalin/saline delivery and prevent
confounding effects of anesthesia. A minimum of 1 hour
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vior testing, and a minimum of 6 rats underwent beha-
vioural testing at each time point.
Mechanical Sensitivity
Mechanical withdrawal thresholds were tested using a
Dynamic Plantar Aesthesiometer (Ugo-Basile, Milan). In
brief, rats were placed in clear acrylic boxes (22 × 16.5
× 14 cm) with a metal grid floor in a temperature con-
trolled room (22°C) and were acclimatized for 15 min-
utes before testing. The stimulus was applied via a metal
filament (0.5 mm) which applied a linearly increasing
force ramp (2.5 g/s) to the middle of the plantar surface
of the hind paw (within the sural nerve territory). A
cut-off of 50 g was imposed to prevent any tissue
damage. The force necessary to elicit a paw withdrawal
was recorded. The paw withdrawal threshold was calcu-
lated as the average of three consecutive tests with at
least 5 minutes between each test. Mechanical allodynia
was defined as reduced threshold after induction of dia-
betes/spinal nerve ligation compared to a baseline paw
withdrawal threshold.
Thermal Hyperalgesia
To quantitatively assess the thermal threshold of the
hindpaw, rats were placed on the glass surface of a ther-
mal testing apparatus with acclimatization for 15 min-
utes before testing. A mobile radiant heat source
(Hargreaves apparatus) located under the glass was
focused onto the middle of each of both individual hind-
paws (within the sural nerve territory) for each rat for
up to 60 seconds, with the latency (seconds) to withdra-
wal measured. Heating rate ramped from 30°C to 58°C
over 60 seconds in consistent fashion on each occasion.
The cutoff of 60 seconds was used to prevent potential
tissue damage. Paws were inspected before and after
thermal testing to ensure that no evidence of thermal
damage was present. The mean withdrawal latency of
both hindpaws from three consecutive trials was calcu-
lated as the thermal threshold. There were 5 minute
intervals provided between each trial.
Locomotor Behavioral Testing
Potential changes in the locomotor function of the rats
related to neuropathic pain states or therapeutic inter-
vention were evaluated using Rotarod testing (Micropro-
cessor Controlled Rota-Rod Treadmill for Rats, Model
57602, Ugo Basile, Italy). Acclimatization for walking on
the revolving drum was performed over three training
trials on the revolving drums at 10-15 rpm over three
consecutive days. A maximum of 150 seconds for each
Rotarod trial was used. The Rotarod performance time
was measured at 1) 0.5, 1, 1.5, and 2 hours after intrana-
sal pregabalin delivery following 72 hours of twice daily
intranasal pregabalin/saline delivery; 2) 72 hours after
initiation of intrathecal pregabalin/saline; and 3) 72
hours after near nerve pregabalin/saline delivery, each
using varying doses of pregabalin (low (0.051 mg/kg/d),
medium (0.51 mg/kg/d) or high dose (2.04 mg/kg/d)) or
saline. The timepoint of after 72 hours was selected as
occurring at least 5 half lives for pregabalin. Each test
was performed at 5-10 minute intervals, and the average
values obtained were compared. A total of 6 rats in each
group were studied for locomotor activity, each of which
had diabetes induced 7 days prior. A control rat cohort
was studied 7 days after diabetes induction without any
exposure to pregabalin or saline.
Surgical harvesting
Following 3 days after the last behavioral testing (4 days
after completion of pregabalin/saline), rats from each
cohort were sacrificed using pentobarbital intraperito-
neal injections-a delay of four days was selected in order
to assess the chronic effects of pregabalin delivery more
than five half lives after pregabalin/saline termination,
rather than detect any acute effects of pregabalin deliv-
ery. The following tissues were harvested from all rats:
dorsal lumbar spinal cord from L2-S1 (left/right), bilat-
eral lumbar DRG from L4-L6, bilateral sciatic nerves,
bilateral sural nerves, and thalamus and primary sensory
cortex (contralateral to injury in rats subjected to spinal
nerve ligation). In diabetic/non-diabetic rats, left-sided
tissues were placed in 2% Zamboni’s fixative for later
immunohistochemistry studies, while right-sided tissues
were immediately fresh frozen at -80°C (Invitrogen, Bur-
lington, ON) in liquid nitrogen and stored at -80°C for
later protein/mRNA identification. In spinal nerve liga-
t i o n / s h a mr a t s ,r i g h ts i d e dt i ssues ipsilateral to spinal
nerve ligation were divided equally to be placed in 2%
Zamboni’s fixative or fresh frozen; left sided tissues were
treated similarly.
Double Ligation Experiment
In order to examine the potential trafficking of CaVa2δ-
1 anterograde from the dorsal root ganglia, an additional
experiment was performed using two nerve ligations-
spinal nerve ligation was performed along with ligature
placed at the dorsal root. Although spinal nerve ligation
forms a model of neuropathic pain, nerve ligation is also
a well established method for determination of axonal
protein trafficking, which when perturbed, leads to pro-
tein accumulation at the ligation site.
Twelve male Sprague Dawley rats had spinal nerve
ligation performed (as above); another four rats had
only dorsal root ligation performed (see below) another
4 rats had sham (used as controls) surgery performed
(as above). Again, the right L5/6 lumbar spinal nerves of
male Sprague Dawley rats (200 g) were exposed in iso-
flurane/oxygen-anesthetised rats followed by tight liga-
tion with 5.0 silk sutures between the DRG and
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receiving sham surgeries and for 8 of the 12 rats receiv-
ing spinal nerve ligation, ligation of the right L5/6 dorsal
roots was performed as well using an additional lami-
nectomy and dural splitting at the L4-6 intervertebral
foramina in order to expose the dorsal roots. Dorsal
root ligation was also performed in 4 rats not receiving
spinal nerve ligation. Tight ligation with 5.0 silk sutures
was performed for the dorsal root at the midpoint
between the dorsal root ganglia and the dorsal horn of
the spinal cord. Intrathecal delivery (see above) was per-
formed for all 16 mice receiving procedures. Surgeons
were blinded as to the contents of the infusion pumps
placed, which were randomized to either contain prega-
balin (high dose (8.0 μmol or 2.04 mg/kg)) or saline in a
1:1 ratio for those rats receiving both spinal and dorsal
root nerve ligation procedures. For the 8 rats receiving
one of spinal nerve ligation or dorsal root ligation, only
intrathecal saline delivery was provided. Closure of the
dura used 9-0 silk sutures, with surgical closure of the
back of each rat performed otherwise as described
above. Pregabalin or saline delivery began immediately
post-surgery, considered day 0. The four rats with only
a sham procedure performed were used as controls and
did not receive any intrathecal delivery.
After 7 days, the following tissues were harvested from
all rats: dorsal lumbar spinal cord from L2-S1 (left/
right), dorsal root proximal to dorsal root ligature, dor-
sal root distal to dorsal root ligature, spinal nerve proxi-
mal to spinal nerve ligation, and spinal nerve distal to
dorsal root ligature. The tissues from one rat from each
g r o u pw e r eu s e df o ri m m u n o h i stochemistry studies to
identify CaVa2δ-1 (see below), while the tissues from
the other 3 rats in each group were placed in liquid
nitrogen and stored at -80°C for later protein (CaVa2δ-1
and b-actin) identification. Due to the small amount of
tissues obtained, pooling of tissues from the rats within
each cohort was required for Western blot analysis (see
below).
Immunohistochemistry
After spinal cord/DRG/peripheral nerve specimens were
fixed in 2% Zamboni’s fixative overnight at 4°C, they
were washed in PBS, kept overnight in 25% sucrose PBS
solution, and then embedded in optimal cutting tem-
perature embedding solution (Tissue Tek, Sakura Fine-
tek, USA), before storage at -80°C until sectioning.
Cryostat transverse and longitudinal nerve sections (10
μm) were placed onto poly-l-lysine-and acetone-coated
slides (SuperFrost Plus, Fisher Scientific, USA). Antigen
retrieval was performed with slides placed in sodium
citrate in an 80°C water bath, a PBS wash for 5 min,
blocking with 10% goat serum for 1 h, and further PBS
washing. In all cases, slides were incubated with primary
antibody overnight at 4°C. After PBS washing, secondary
fluorescent antibody was applied with incubation for 1 h
at room temperature, followed by PBS washing and slide
mounting. All immunohistochemistry was visualized
using a Zeiss Imager Z1 (Zeiss, UK) fluorescence micro-
scope. Calculation of the number of immunofluorescent
profiles as well as the relative luminosity was performed
using Adobe Photoshop (Adobe Photoshop 9.0, Adobe,
San Jose, CA, 2005).
Primary antibodies used were to identify CaVa2δ-1
(1:200, produced in rabbit, Lifespan Biosciences, Seattle,
WA), glial fibrillary acidic protein (GFAP) for Schwann
cell identification (1:200, produced in mouse, Sigma
Aldrich Canada, Oakville, ON), neurofilaments (NF) 200
for axon and neuron identification (1:100, produced in
mouse, Santa Cruz, Santa Cruz, CA), goat anti-ionized
calcium-binding adaptor molecule 1 (Iba-1) (1:1000,
produced in goat, Abcam, Cambridge, MA) and micro-
tubule associated protein-2 (MAP-2) (1:500, produced in
rabbit, Sigma Aldrich Canada). Secondary antibodies
used were either anti-rabbit IgG fluorescein isothiocya-
nate (FITC) labelled (1:100; Zymed, San Francisco, CA),
donkey anti-goat IgG CY3 labeled (1:200, Fitzgerald
Industries, Concord, MA), or goat anti-mouse IgG CY3
labeled (1:200, Sigma Aldrich Canada, Oakville, ON).
Slides were cover-slipped with Vectashield mounting
medium containing DAPI for nuclear identification
(Vector Laboratories, CA, USA). Iba-1, MAP-2 and
GFAP-positive cells were determined by counting the
number of profiles (cell bodies) as described previously
[10].
Samples of spinal cord/DRG/spinal nerve prepared for
immunohistochemistry were examined for expression of
CaVa2δ-1 along with identification of cell types (GFAP,
MAP-2, NF200). For identification of microglia, isolated
staining with Iba-1 was performed. Calculation of the
number of immunofluorescent fibers as well as the
luminosity of individual nerve fibers was performed for
CaVa2δ-1. From each of the L4-6 DRGs, neurons were
counted in six sections through the midportion of the
DRG: total neuron numbers per transverse section, total
numbers of neurons immunolabeled, and numbers of
neurons with intense expression of channel of interest,
as defined using two previously defined cutoff values
with Adobe Photoshop [10]. Dorsal root ganglia neurons
were counted as those with nuclear profiles that were
visible in one section, but not in the subsequent section.
Sensory neurons were differentiated from satellite and
Schwann cells based on size and appearance as well as
positive immunoprofiling for NF200. Total neuronal
number was then calculated based upon the summation
of neurons with newly identified nuclei identified
through all sections of an individual dorsal root gang-
lion. All counting was performed with the microscopist
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these measures were easily distinguished among immu-
nolabeled neurons by a single examiner blinded to the
identity of the groups using a calculated luminosity
measurement of fluorescence for individual fibers exam-
ined under 400 × magnifications. Luminosity was classi-
fied as none-low (luminosity value of 0-150), moderate
(150-250) or high (> 250) using Adobe Photoshop soft-
ware (scale of 0-255 with arbitrary units).
Transverse sections through the lumbar spinal cord
were also immunolabeled for channel expression with
specific attention directed toward the dorsal horn. The
relative fluorescence intensity was measured for each
side ipsilateral and contralateral to spinal nerve ligation
injury, or bilaterally for diabetic rats, at a pre-deter-
mined exposure time with a digital camera (Zeiss Axio-
scope, Zeiss) which provided an image of the entire
spinal cord. Luminosity of each dorsal quadrant of the
spinal cord was calculated using Adobe Photoshop [10].
In dorsal spinal cord regions within the thoracic and
lumbar regions, the total numbers of microglia per
transverse section were identified using Iba-1 immuno-
histochemistry. The lateral, central and medial dorsal
horn regions, representing laminae 1-3, were examined.
For cellular densities, a box measuring 10
4 μm
2 was
placed onto areas of dorsal horn for regions between T2
and S1. A quantitative estimate (proportional area) of
changes in the activation state of microglial cells was
performed [77-79] in the dorsal spinal cord based on
atlas boundaries and after subtraction of background
signal. A resting microglia was classified as having a
small, compact soma with long, thin, ramified processes.
Activated microglia, in contrast, exhibit marked cellular
hypertrophy, and retracted processes with process length
less than soma diameter. A total of 25 randomly chosen
areas of dorsal spinal cord, from a minimum of 4 ani-
mals per cohort group, were examined for activated
microglia quantification. All measurements were per-
f o r m e db yas i n g l ee x a m i n e rb l i n d e dt ot h eg r o u p
identity.
Western Immunoblotting
In order to determine protein expression for mem-
brane bound channels, we performed Western blot
with a specialized protocol to protect membrane struc-
ture. Tissue portions from the dorsal spinal cord,
DRG, thalamus and primary sensory cortex were
placed in chilled phosphate buffer solution (PBS), fol-
lowed by centrifugation at 400 rpm. Tissue was ground
down with a pestle in ice-cold lysis buffer (HEPES 15
mM at pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 1 mM
2Na-EDTA, 5% glycerol, 0.5% Nonidet 40 (NP-40), 1
mM Phenylmethylsulfonyl Fluoride, Roche Mini-Com-
plete Protease Inhibitors, and double distilled H20) at
a ratio of 1 g of tissue: 10 ml of lysis buffer. Centrifu-
gation of samples at 5,000 rpm followed for 15 min-
utes at 4°C. Supernatant was kept in tubes, and the
pellet was homogenized again with half amounts of
lysis buffer, followed by repeat centrifugation at 5,000
rpm for 15 minutes at 4°C. Both supernatants were
transferred to ultracentrifuge rubes for repeat centri-
fuge at 26,000 rpm for 15 minutes at 4°C. Pellets were
taken and resuspended in 25-50 μlo fr e s u s p e n s i o n
buffer (75 mM Tris at pH 7.4, 12.5 mM MgCl2,5m M
2Na-EDTA, 1.5% SDS, 0.1% Triton X-100, and double
distilled H20) for protein quantification. These protein
samples were then separated by SDS-PAGE techniques
under conditions previously described [34]. Blots were
probed for CaVa2δ-1 (1:4000, produced in rabbit, Life-
span Biosciences, Seattle, WA). For a loading control,
anti-b-actin (1:100, Biogenesis Ltd. Poole, UK) was
analyzed as well. Signal detection was performed by
exposing of the blot to enhanced chemi-luminescent
reagents (Amersham, GE Healthcare, USA) and cap-
tured on Kodac X-OMAT K film. In each case, 4-6
blots were performed for each protein of interest from
different rats in each cohort. Blots were analyzed with
Adobe Photoshop (Adobe Photoshop 9.0, Adobe, San
Jose, CA, 2005) for semi-quantification of blotting den-
sity [34].
Quantitative Reverse-Transcriptase Polymerase Chain
Reactions
Total RNA was extracted from peripheral nerve and
spinal cord regions using Trizol reagent (Invitrogen).
Total RNA (1 μg) was processed directly to cDNA
synthesis using the Superscript II Reverse Transcrip-
tase
® system (Invitrogen). CACNA2D1 primers were:
Forward 5’-GAAAGGCTTTAGCTTCGCGTTT-3’,
Reverse 5’-TCTCTCTTCTCCTCCATCCGTG-3’ [Gen-
Bank: NM_001110847.1]. For a housekeeping gene, ribo-
somal protein (large P0) (RPLP0) was used, with
primers: Forward 5’-TACCTGCTCAGAACACCG
GTCT-3’, Reverse 5’-GCACATCGCTCAGGATTTCAA-
3’ [GenBank: NM_022402.2]. qRT-PCR was done using
SYBR Green dye. All reactions were performed in dupli-
cate in an ABI PRISM 7000 Sequence Detection System.
Data were calculated by the 2
-ΔΔCT method and are pre-
sented as the fold induction of mRNA for the specific
target in diabetic tissues normalized to RPLP0 and com-
pared to control tissues (defined as 1.0-fold). The 2
-
ΔΔCT method is a standard technique to permit analysis
of quantitiative real-time polymerase chain reaction
results; this is an approximation technique which
assumes similar efficiencies of reactions for both stan-
dard and target genes, permitting comparisons of differ-
ences in messenger RNA quantities following
polymerase chain reactions after baseline measurements.
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The presence of multiple doses of pregabalin within
each intervention led to the use of two-way repeated
unmatched ANOVA measurements followed by Tukey’s
test were performed for analysis of behavioural studies.
We chose to analyze behavioral data based upon com-
parison of either low (0.051 mg/kg/d), medium (0.51
mg/kg/d) or high dose (2.04 mg/kg/d) pregabalin inter-
vention with either the sham group (for spinal nerve
ligation) or non-diabetic cohort group as appropriate.
For immunohistochemistry, we chose to analyze the tis-
sues from rodents receiving the highest doses for each
intervention with those tissues from rats receiving pla-
cebo using mean values-therefore, one-way unmatched
ANOVA followed by Tukey’s test was used for immuno-
histochemistry analysis as well. Data collected in the
groups were expressed as mean ± standard error in all
cases. For immunohistochemistry comparisons demon-
strated as low/medium/high intensity, the individual
values were compared using unmatched ANOVA test-
ing. Bonferroni corrections were applied as appropriate
in all cases.
Additional material
Additional file 1: Supplementary Figure 1- Pregabalin Detection.
Concentrations of pregabalin within specific regions of the brain and
spinal cord in the hours after delivery of either intranasal or intrathecal
pregabalin were measured beginning at 72 hours after initiation of either
therapy. Intranasal (A) pregabalin delivery led to peak tissue
concentrations of pregabalin at about the 74 hour timepoint, 2 hours
after most recent intranasal delivery before falling at the 77 hour
timepoint; intranasal delivery led to highest concentrations in the
cerebral structures. Intrathecal pregabalin delivery (B) led to
concentrations that were essentially stable over time and greatest in the
lumbar cord region. Doses provided through either intranasal or
intrathecal delivery were comparable to medium doses (0.51 mg/kg/d) of
pregabalin in later subexperiments. [n = 3-4 rats in each rat cohort for
each time point].
Additional file 2: Supplementary Figure 2-CaVa2δ-1 nerve
immunohistochemistry. Co-localized immunohistochemistry pictures for
CaVa2δ-1 demonstrated for sciatic peripheral nerve of control (non-
diabetic) rat (A) or diabetic rat (B), and spinal nerve of control (no injury)
rat (C) or spinal nerve nerve distal to spinal nerve ligation (D). Axonal
fibers are demonstrated with neurofilament 200 (NF200) (red), Schwann
cells with glial fibrillary acidic protein (GFAP) (green), and CaVa2δ-1
presence is also demonstrated (blue). Axons expressing CaVa2δ-1 appear
purple-blue after co-localization of images. A bar graph demonstrates a
greater number of CaVa2δ-1 positive sciatic fibers in diabetic nerve with
diabetic peripheral neuropathy (DPN) (E) and in spinal nerve at or distal
to spinal nerve ligation (SNL) when compared to control rat nerve (F).
There was no impact of pregabalin interventions upon expression of
CaVa2δ-1 within the peripheral nerve itself distal to the site of traumatic
injury when compared to saline delivery (values are mean ± S.E.M.,
unmatched ANOVA testing between intervention groups, * indicates a
significant difference between the control rat group as compared to
each of the intervention groups receiving either pregabalin or saline (p <
0.0125 after Bonferroni corrections). Bar = 10 μm.
Additional file 3: Supplementary Figure 3-CaVa2δ-1 dorsal root
ganglia immunohistochemistry. Co-localized immunohistochemistry
pictures demonstrating DRG neurons of control (non-diabetic) rat (A),
diabetic rat (B), control (no injury) rat (C), and DRG ipsilateral to spinal
nerve ligation (D). Neurons are demonstrated with neurofilament 200
(NF200) (red), while CaVa2δ-1 presence is also demonstrated (green).
Neurons expressing CaVa2δ-1 appear yellow-green after co-localization of
images. A bar graph demonstrates a greater number of medium-high
CaVa2δ-1 expressing DRG neurons ipsilateral to spinal nerve ligation
(SNL) (E) and in diabetic DRG neurons with diabetic peripheral
neuropathy (DPN) (F). There was no impact of pregabalin interventions
upon expression of CaVa2δ-1 within the DRG neurons themselves when
compared with saline interventions (values are mean ± S.E.M.,
unmatched ANOVA testing between intervention groups, * indicates a
significant difference between the control rat group as compared to
each of the intervention groups receiving pregabalin or saline (p <
0.0125 after Bonferroni corrections). Bar = 10 μm.
Additional file 4: Supplementary Figure 4-Central nervous system
CaVa2δ-1 protein detection. Western blotting identified no increase in
levels of CaVa2δ-1 protein in either the thalamus or sensory cortex for
rats exposed to either diabetic peripheral neuropathy (DPN) or spinal
nerve ligation (SNL) when compared to control rats. Levels of CaVa2δ-1
protein in the thalamus and sensory cortex were also unchanged with
either intrathecal or intranasal delivery of high dose (2.04 mg/kg/d)
pregabalin or with saline delivery. b-actin was used as a loading control
as displayed.
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